Neuroblastoma (NB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Neuroblastoma (NB) Market Outlook

Thelansis’s “Neuroblastoma (NB) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuroblastoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Neuroblastoma (NB) Overview

Neuroblastoma is a malignant tumor that arises from neural crest cells, which give rise to the sympathetic nervous system, and occurs mainly in children. The prognosis of neuroblastoma is affected by various genetic anomalies, such as amplification of the oncogene MYCN, numerical abnormalities of chromosomes and segmental chromosomal anomalies (including loss from 1p, from 11q, or gains of 17q). Diagnosis is based on elevated metabolites of urinary catecholamines and imaging of the initial tumor by ultrasound, brain scan, or MRI. MIBG scintigraphy and medullary analysis are useful for detecting metastases. Nephroblastoma is a differential diagnosis. Bone pain and limp can be misinterpreted as synovitis of the hip, and bilateral peri-orbital hematomas should not be mistaken for maltreatment. The prognosis of neuroblastoma is poor for approximately 60% of children over one year of age who present with metastatic disease at diagnosis, even with intensive treatment. The five-year survival rate for children over one year of age ranges from 95% for some localized tumors to 30% in cases of metastatic neuroblastoma.

• It represents about 10% of solid tumors in infants and children under 15, with an annual incidence of approximately 1/70,000 in children in this class of age.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: